MX2017003819A - Macrociclos peptidomimeticos y formulaciones de los mismos. - Google Patents

Macrociclos peptidomimeticos y formulaciones de los mismos.

Info

Publication number
MX2017003819A
MX2017003819A MX2017003819A MX2017003819A MX2017003819A MX 2017003819 A MX2017003819 A MX 2017003819A MX 2017003819 A MX2017003819 A MX 2017003819A MX 2017003819 A MX2017003819 A MX 2017003819A MX 2017003819 A MX2017003819 A MX 2017003819A
Authority
MX
Mexico
Prior art keywords
disclosed
formulations
peptidomimetic macrocycles
pharmaceutical formulations
aqueous pharmaceutical
Prior art date
Application number
MX2017003819A
Other languages
English (en)
Inventor
Rhodes Chris
Darlak Krzysztof
Allen Annis David
KANAI Sonoko
Hoernschemeyer Joerg
Grass Michaela
Original Assignee
Aileron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aileron Therapeutics Inc filed Critical Aileron Therapeutics Inc
Publication of MX2017003819A publication Critical patent/MX2017003819A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Se describen formulaciones farmacéuticas acuosas, para administración parenteral, que comprenden macrociclo peptidomimético o una sal farmacéuticamente aceptable del mismo en donde el macrociclo peptidomimético enlaza a proteínas MDM2 y/o MDMX. También se describen métodos para tratar enfermedades y trastornos usando las formulaciones farmacéuticas acuosas descritas en la presente.
MX2017003819A 2014-09-24 2015-09-24 Macrociclos peptidomimeticos y formulaciones de los mismos. MX2017003819A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462054842P 2014-09-24 2014-09-24
PCT/US2015/052018 WO2016049355A1 (en) 2014-09-24 2015-09-24 Peptidomimetic macrocycles and formulations thereof

Publications (1)

Publication Number Publication Date
MX2017003819A true MX2017003819A (es) 2017-06-15

Family

ID=55582019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003819A MX2017003819A (es) 2014-09-24 2015-09-24 Macrociclos peptidomimeticos y formulaciones de los mismos.

Country Status (12)

Country Link
US (3) US10905739B2 (es)
EP (1) EP3197477A4 (es)
JP (3) JP2018503595A (es)
KR (1) KR102570210B1 (es)
CN (2) CN107106642B (es)
AU (1) AU2015320545C1 (es)
BR (1) BR112017005736A2 (es)
CA (1) CA2961029A1 (es)
IL (1) IL251122B (es)
MX (1) MX2017003819A (es)
SG (2) SG11201702175YA (es)
WO (1) WO2016049355A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960506B2 (en) 2006-12-14 2011-06-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN109627287A (zh) 2007-02-23 2019-04-16 爱勒让治疗公司 ***大环***
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
KR102570210B1 (ko) 2014-09-24 2023-08-23 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 제제
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
JP2018516844A (ja) * 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2996685A1 (en) * 2015-09-03 2017-03-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11306130B2 (en) 2016-04-01 2022-04-19 Arizona Board Of Regents On Behalf Of The University Of Arizona PAR3 mimetic peptides and uses thereof
WO2017205786A1 (en) * 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
US20170360881A1 (en) * 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2018098534A1 (en) * 2016-12-02 2018-06-07 Garvan Institute Of Medical Research Methods of treating cancer and reagents thereof
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
TW202033213A (zh) * 2018-10-24 2020-09-16 美商雅利斯塔製藥公司 脂聯素擬肽調配物
JP2022525416A (ja) * 2019-03-15 2022-05-13 エイルロン セラピューティクス，インコーポレイテッド ペプチド模倣大環状分子およびその使用
US20230330238A1 (en) * 2020-10-14 2023-10-19 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use

Family Cites Families (373)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000259A (en) 1975-06-16 1976-12-28 American Home Products Corporation Cyclic dodecapeptide analogs of somatostatin and intermediates
US4438270A (en) 1977-07-11 1984-03-20 Merrell Toraude Et Compagnie α-Halomethyl derivatives of α-amino acids
US4191754A (en) 1979-02-28 1980-03-04 Merck & Co., Inc. Bicyclic somatostatin analogs
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
AU550730B2 (en) 1982-03-09 1986-04-10 Commonwealth Of Australia, The Automated metal detection
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4730006A (en) 1986-01-27 1988-03-08 Merrell Dow Pharmaceuticals Inc. Derivatives of 2,6-diamino-3-haloheptanedioic acid
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
WO1989009233A1 (en) 1988-03-24 1989-10-05 Terrapin Technologies, Inc. Molecular sticks for controlling protein conformation
US5094951A (en) 1988-06-21 1992-03-10 Chiron Corporation Production of glucose oxidase in recombinant systems
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
US5120859A (en) 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5712418A (en) 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5245009A (en) 1990-03-23 1993-09-14 The Salk Institute For Biological Studies CRF antagonists
CA2047042A1 (en) 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
CZ61893A3 (en) 1990-10-11 1994-01-19 Boehringer Ingelheim Kg Cyclopeptides, process of their preparation and their use as medicaments
DE69118826T2 (de) 1990-11-27 1996-11-14 Fuji Photo Film Co Ltd Propenamidderivate, deren Polymere, Copolymere und deren Verwendung
US5124454A (en) 1990-11-30 1992-06-23 Minnesota Mining And Manufacturing Company Polycyclic diamines and method of preparation
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
AU1570292A (en) 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
GB9114949D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Novel compounds
DE69220861T2 (de) 1991-08-13 1997-11-20 Takeda Chemical Industries Ltd Zyklische Peptide und ihre Verwendung
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
IL103252A (en) 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0552417B1 (en) 1991-11-19 1999-07-07 Takeda Chemical Industries, Ltd. Cyclic peptides and use thereof
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
EP1253156A3 (en) 1992-04-03 2004-01-07 California Institute Of Technology High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis and application thereof
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5679641A (en) 1992-05-26 1997-10-21 Rijksuniversiteit Leiden Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
EP0691987A1 (en) 1993-03-29 1996-01-17 The Du Pont Merck Pharmaceutical Company CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
WO1994025482A1 (en) 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
CN1141059A (zh) 1993-11-22 1997-01-22 昂尼克斯药物公司 P53-结合多肽和编码该多肽的多核苷酸
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
EP0746557A4 (en) 1994-02-18 1997-05-02 Cell Therapeutics Inc INTRACELLULAR SIGNALING MEDIATORS
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
US7553929B2 (en) 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5702908A (en) 1994-07-20 1997-12-30 University Of Dundee Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
EP1956374A1 (en) 1994-09-19 2008-08-13 Ricardo J. Moro Detection and treatment of cancer
CA2209183A1 (en) 1994-12-29 1996-07-11 Joel L. Pomerantz Chimeric dna-binding proteins
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
EP0729972A1 (de) 1995-02-28 1996-09-04 F. Hoffmann-La Roche Ag Tetrahydronaphthalin-Peptidderivate
US6514942B1 (en) 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5675001A (en) 1995-03-14 1997-10-07 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
PT832096E (pt) 1995-05-04 2002-01-30 Scripps Research Inst Sintese de proteinas atraves de ligacao quimica nativa
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
FR2738151B1 (fr) 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
GB9521544D0 (en) 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
AU6162996A (en) 1996-01-17 1997-08-11 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides and peptidomimetics by catalytic ring closing metathesis
US5849954A (en) 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
US5849691A (en) 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
JP3792777B2 (ja) 1996-05-10 2006-07-05 株式会社カネカ １−アルコキシカルボニル−３−フェニルプロピル誘導体の製造方法
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US5663316A (en) 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
WO1998001467A2 (en) 1996-07-05 1998-01-15 Novartis Ag Inhibitors of the interaction between p53 and mdm2
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
WO1998017625A1 (fr) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Nouveaux remedes pour des maladies infectieuses
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
JP2001504831A (ja) 1996-11-21 2001-04-10 プロメガ・コーポレーション アルキルペプチドアミドおよび適用
CZ290347B6 (cs) 1997-02-07 2002-07-17 Ústav organické chemie a biochemie AV ČR Cyklopeptidy stimulující uvolňování růstového hormonu a způsob jejich přípravy
CN1252808A (zh) 1997-02-20 2000-05-10 耶达研究及发展有限公司 抗病原合成肽及包含该肽类的组合物
US6849428B1 (en) 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
EP1015479A4 (en) 1997-04-11 2002-07-24 Lilly Co Eli COMBINATIVE SUBSTANCE LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND THE RELATED METHODS
GB9708092D0 (en) 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
CA2289960A1 (en) 1997-05-15 1998-11-19 Kyowa Hakko Kogyo Co., Ltd. Peptides having a cyclic structure and restoring the activities of p53 protein to mutant p53 protein
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
JP2001524301A (ja) 1997-09-17 2001-12-04 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ 新規治療用分子
CA2305809A1 (en) 1997-09-26 1999-04-08 University Technologies International, Inc. Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6875594B2 (en) 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
US6177076B1 (en) 1997-12-09 2001-01-23 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
US6362276B1 (en) 1998-01-07 2002-03-26 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6030997A (en) 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
CZ20003798A3 (cs) 1998-04-15 2001-08-15 Aventis Pharmaceuticals Products, Inc. Způsob výroby cyklických peptidů vázaných k polymernímu nosiči
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
CA2360671A1 (en) 1999-01-29 2000-08-03 The Board Of Trustees Of The University Of Illinois P53 inhibitors and therapeutic use of the same
US6372490B1 (en) 1999-02-23 2002-04-16 Curagen Corporation Nucleic acid encoding the MDM interacting protein
EP1216309A2 (en) 1999-03-01 2002-06-26 Variagenics, Inc. Methods for targeting rna molecules
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
AU5161800A (en) 1999-05-24 2000-12-12 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
DE60026576T2 (de) 1999-12-16 2007-01-18 Chugai Seiyaku K.K. VERFAHREN ZUM AUFFINDEN EINES HEILMITTELS FÜR KREBS MIT HILFE VON INTERAKTIONSDOMÄNEN VON p53 UND MORTALIN
DE10009341A1 (de) 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
US6495674B1 (en) 2000-02-25 2002-12-17 The Salk Institute For Biological Studies Evectins and their use
US7166712B2 (en) 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
US7049290B2 (en) 2000-07-28 2006-05-23 Universität Zürich Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
US20040228866A1 (en) 2000-08-04 2004-11-18 Ludwig Institute For Cancer Research Suppressor genes
AU2001284942A1 (en) 2000-08-16 2002-02-25 Georgetown University Medical Center Small molecule inhibitors targeted at bcl-2
AU2001273385B2 (en) 2000-09-08 2005-04-07 Gryphon Therapeutics, Inc. Polymer-modified synthetic proteins
CA2432111A1 (en) 2000-12-19 2002-08-22 The Johns Hopkins University Jfy1 protein induces rapid apoptosis
BR0207502A (pt) 2001-02-23 2004-03-09 Polyphor Ltd Compostos, enanciÈmeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos
GB0104588D0 (en) 2001-02-24 2001-04-11 Univ Dundee Novel p-53 inducible protein
DE10109813A1 (de) 2001-03-01 2002-09-12 Thomas Stanislawski Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen
AU2002252246A1 (en) 2001-03-09 2002-09-24 University Of Louisville Helicomimetics and stabilized lxxll peptidomimetics
JPWO2003014056A1 (ja) 2001-08-08 2004-11-25 鐘淵化学工業株式会社 光学活性２−置換カルボン酸の製造法
US20040106548A1 (en) 2001-09-07 2004-06-03 Schmidt Michelle A Conformationally constrained labeled peptides for imaging and therapy
US20020045192A1 (en) 2001-09-19 2002-04-18 St. Jude Children's Research Hospital Arf and HDM2 interaction domains and methods of use thereof
CN101157924A (zh) 2001-12-11 2008-04-09 人体基因组科学有限公司 嗜中性白细胞因子α
EP1321474A1 (en) 2001-12-18 2003-06-25 Universite De Geneve A method for inducing apoptosis
AU2002364364A1 (en) 2001-12-31 2003-07-24 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
IL162604A0 (en) 2002-01-03 2005-11-20 Yissum Res Dev Co Conformationally constrained c-backbone cyclic peptides
US7432242B2 (en) 2002-02-15 2008-10-07 The Regents Of The University Of Michigan Inhibitors of RGS proteins
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
US7498134B2 (en) 2002-03-30 2009-03-03 The Trustees Of Columbia University In The City Of New York HAUSP-Mdm2 interaction and uses thereof
ATE394674T1 (de) 2002-04-22 2008-05-15 Univ Florida Funktionalisierte nanopartikel und verwendungsverfahren
WO2003095625A2 (en) 2002-05-13 2003-11-20 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
AU2003240482B2 (en) 2002-05-30 2009-03-12 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
WO2003102538A2 (en) 2002-05-30 2003-12-11 European Molecular Biology Laboratory Combinatorial chemical library ii
US7208154B2 (en) 2002-06-03 2007-04-24 Regents Of The University Of Michigan Methods and compositions for the treatment of MHC-associated conditions
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20060051846A1 (en) 2002-09-06 2006-03-09 Kaneka Corporation Process for producing l-alpha-methylcysteine derivative
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
WO2004026896A2 (en) 2002-09-23 2004-04-01 Medivir Ab Hcv ns-3 serine protease inhibitors
AU2003299132A1 (en) 2002-10-07 2004-04-23 Genome Research Limited P53 binding polypeptide
CN101003459B (zh) 2002-10-24 2011-08-10 陶氏环球技术有限责任公司 烯烃易位产物混合物的稳定
EP2135867B1 (en) 2002-11-07 2013-09-25 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same
AU2003276234B2 (en) 2002-11-08 2007-04-19 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as PPAR agonists
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2517285A1 (en) 2003-02-26 2004-09-10 Japan Science And Technology Agency Transcriptional factor inducing apoptosis in cancer cell
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7632920B2 (en) 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
AU2003902743A0 (en) 2003-06-02 2003-06-19 Promics Pty Limited Process for the preparation of cyclic peptides
WO2005000876A2 (en) 2003-06-27 2005-01-06 Proteologics, Inc. Ring finger family proteins and uses related thereto
WO2005007675A2 (en) 2003-07-09 2005-01-27 The Scripps Research Institute TRIAZOLE ϵ-AMINO ACIDS
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
US7695426B2 (en) 2003-08-20 2010-04-13 Biological Resources Pty Ltd Methods for enhancing viability
WO2005032471A2 (en) 2003-10-03 2005-04-14 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
US20070207947A1 (en) 2003-10-16 2007-09-06 Aplagen Gmbh Stabilized Peptides
WO2005044840A2 (en) 2003-10-17 2005-05-19 The Cbr Institute For Biomedical Research, Inc. Modulation of anergy and methods for isolating anergy-modulating compounds
US7273927B2 (en) 2003-11-03 2007-09-25 University Of Massachusetts Mdm2 splice variants
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
WO2005074521A2 (en) 2004-01-30 2005-08-18 The Trustees Of Columbia University In The City Of New York C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF
GB0404731D0 (en) 2004-03-03 2004-04-07 Indp Administrative Inst Nims Method and products for the selective degradation of proteins
EP1737884B1 (en) 2004-03-19 2016-10-19 The University Of Queensland Alpha helical mimics, their uses and methods for their production
ATE414693T1 (de) 2004-05-18 2008-12-15 Hoffmann La Roche Neuartige cis-imidazoline
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
CN100335467C (zh) 2004-06-04 2007-09-05 中国科学院上海有机化学研究所 一锅法区域选择性合成5－碘代－1，4－二取代－1，2，3－三氮唑化合物
WO2005118634A2 (en) 2004-06-04 2005-12-15 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity against beta-amyloid production
EP1602663A1 (en) 2004-06-04 2005-12-07 Chiralix B.V. Triazole-linked glycoamino acids and glycopeptides
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
US9598470B2 (en) 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
MX2007005176A (es) 2004-10-29 2007-06-25 Schering Corp 5-carboxiamida pirazoles y [1,2,4]triazoles sustituidos como agentes antivirales.
WO2006069001A2 (en) 2004-12-20 2006-06-29 Baylor College Of Medicine Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands
GB0428187D0 (en) 2004-12-23 2005-01-26 Univ Liverpool Cancer treatment
WO2006078161A1 (en) 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
FR2881430B1 (fr) 2005-02-01 2010-10-22 Servier Lab Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
SG176463A1 (en) 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
EP1891090A2 (en) 2005-06-13 2008-02-27 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
JP2008546689A (ja) * 2005-06-17 2008-12-25 バクスター・インターナショナル・インコーポレイテッド モチリン様ペプチドを含む、安定に緩衝化された薬学的組成物
US20070020620A1 (en) 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
WO2007009191A1 (en) 2005-07-21 2007-01-25 Newsouth Innovations Pty Limited Method for treating cancer
US20070161544A1 (en) 2006-01-06 2007-07-12 Peter Wipf Selective targeting agents for mitcochondria
US7745573B2 (en) 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
US7538190B2 (en) 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
CN101595107A (zh) 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
EP2037919A2 (en) 2006-06-30 2009-03-25 Schering Corporation Method of using substituted piperidines that increase p53 activity
CA2659225A1 (en) 2006-07-26 2008-01-31 Pepscan Systems B.V. Immunogenic compounds and protein mimics
US8614192B2 (en) 2006-07-28 2013-12-24 Leiden University Medical Center Method for treating ocular cancer
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
JP5506386B2 (ja) 2006-09-04 2014-05-28 ユニバーシティー・コート・オブ・ザ・ユニバーシティー・オブ・ダンディー Ｐ５３活性化化合物
US20080213175A1 (en) 2006-09-15 2008-09-04 Kolb Hartmuth C Click chemistry-derived cyclic peptidomimetics as integrin markers
US7897394B2 (en) 2006-09-21 2011-03-01 Intrexon Corporation Endoplasmic reticulum localization signals
ATE467413T1 (de) 2006-09-21 2010-05-15 Hoffmann La Roche Oxindolderivate als antikrebsmittel
AU2007307254A1 (en) 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
US7932397B2 (en) 2006-11-22 2011-04-26 Massachusetts Institute Of Technology Olefin metathesis catalysts and related methods
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7960506B2 (en) 2006-12-14 2011-06-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP2121007A1 (en) 2006-12-21 2009-11-25 Cytos Biotechnology AG Circular ccr5 peptide conjugates and uses thereof
US8633163B2 (en) 2007-01-29 2014-01-21 Polyphor Ltd. Template-fixed peptidomimetics
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
CN101244053B (zh) 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
CN109627287A (zh) 2007-02-23 2019-04-16 爱勒让治疗公司 ***大环***
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
WO2008137633A2 (en) 2007-05-02 2008-11-13 Dana-Farber Cancer Institute, Inc. Methods of modulating cellular homeostatic pathways and cellular survival
WO2008150479A2 (en) * 2007-06-01 2008-12-11 Acologix, Inc. High temperature stable peptide formulation
CA2699707C (en) 2007-09-21 2016-05-17 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
US8871899B2 (en) 2007-12-31 2014-10-28 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
MX2010008110A (es) 2008-01-25 2011-03-04 Trustees Boston College Catalizadores para reacciones de metatesis incluyendo metatesis de olefina enantioselectiva, y metodos relacionados.
DK2245464T3 (en) 2008-01-25 2017-02-20 Multivir Inc P53 BIOMARKETS
BRPI0907754A2 (pt) * 2008-02-08 2015-07-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos terapêuticos
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
EP2310407A4 (en) 2008-04-08 2011-09-14 Aileron Therapeutics Inc BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES
AU2009244400B2 (en) 2008-05-06 2012-12-20 New York Blood Center Antiviral cell penetrating peptides
US20110250685A1 (en) 2008-06-03 2011-10-13 Nash Huw M Compositions and methods for enhancing cellular transport of biomolecules
WO2009149339A2 (en) 2008-06-05 2009-12-10 University Of Maryland, Baltimore P53 activator peptides
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
GB0813873D0 (en) 2008-07-30 2008-09-03 Univ Dundee Compounds
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2334317B1 (en) 2008-09-16 2017-06-14 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
JP2012503013A (ja) 2008-09-18 2012-02-02 ニューヨーク ユニバーシティ ＨＩＦ−１αと水素結合代替ヘリックスを有するｐ３００／ＣＢＰの間の相互作用の阻害
US20120115793A1 (en) 2008-09-22 2012-05-10 Alleron therapeutics, Inc Peptidomimetic macrocycles
EP2334697A1 (en) * 2008-09-22 2011-06-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2342221B1 (en) 2008-09-22 2018-11-07 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
BRPI0918948A2 (pt) 2008-09-22 2015-12-15 Aileron Therapeutics Inc macrociclos peptidomiméticos
WO2010034026A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2737916A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2338056B1 (en) 2008-10-10 2018-01-03 Dana Farber Cancer Institute Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
JP2010120881A (ja) 2008-11-19 2010-06-03 Keio Gijuku ヒト癌タンパク質ＭＤＭ２とヒト癌抑制タンパク質ｐ５３との相互作用阻害ペプチド及びその使用
KR101298168B1 (ko) 2008-11-21 2013-08-20 충남대학교산학협력단 스네일―ｐ５３ 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제
US9458202B2 (en) 2008-11-24 2016-10-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
EP2358748B1 (en) 2008-12-09 2016-07-06 Dana-Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2010083501A2 (en) 2009-01-16 2010-07-22 University Of South Florida Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
FR2942798B1 (fr) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
WO2011005219A1 (en) 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US20120149661A1 (en) 2009-08-26 2012-06-14 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
US20110223149A1 (en) 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
RU2576512C2 (ru) 2009-11-04 2016-03-10 Хэлс Ресеч Инк. Способ и композиции для подавления старения
NZ600430A (en) 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8658170B2 (en) 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
KR101220516B1 (ko) 2010-01-21 2013-01-10 연세대학교 산학협력단 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도
US8598400B2 (en) 2010-02-08 2013-12-03 Massachusetts Institute Of Technology Efficient methods for Z- or cis-selective cross-metathesis
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (en) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
MX2012011600A (es) 2010-04-09 2012-11-30 Univ Michigan Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad.
US20110313167A1 (en) 2010-06-22 2011-12-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Substituted Heterocycles as Therapeutic agents for treating cancer
WO2011163423A2 (en) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012016186A1 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
WO2012033525A2 (en) 2010-09-08 2012-03-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P53-mdm2 antagonists
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
US8957026B2 (en) 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US20130225603A1 (en) 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
CA2813256A1 (en) 2010-09-30 2012-04-05 St. Jude Children's Research Hospital Aryl-substituted imidazoles
US9169295B2 (en) 2010-10-13 2015-10-27 Bristol-Myers Squibb Company Macrocycles and macrocycle stabilized peptides
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
EA201390682A1 (ru) 2010-11-12 2014-01-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Спирооксиндольные антагонисты mdm2
AU2011325910B2 (en) 2010-11-12 2016-03-24 Dana Farber Cancer Institute, Inc. Cancer therapies and diagnostics
WO2012076513A1 (en) 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
WO2012083078A2 (en) 2010-12-15 2012-06-21 The Research Foundation Of State University Of New York Croos-linked peptides and proteins, methods of making same, and uses thereof
WO2012080389A1 (en) 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
WO2012083181A1 (en) 2010-12-16 2012-06-21 Indiana University Research And Technology Corporation Alpha helix mimetics and methods for using
CN103261188A (zh) 2010-12-17 2013-08-21 先正达参股股份有限公司 杀虫化合物
EP2474624B1 (en) 2011-01-05 2016-08-17 Daniela Kandioler Response prediction in cancer treatment (p53 adapted cancer therapy)
EP2474625B1 (en) 2011-01-05 2016-11-02 Daniela Kandioler Method for determining the p53 status of a tumour
JP5950587B2 (ja) 2011-02-28 2016-07-13 キヤノン株式会社 多孔質ガラスの製造方法および光学部材の製造方法
EP2681235B1 (en) 2011-03-04 2016-05-04 New York University Hydrogen bond surrogate macrocycles as modulators of ras
EP2684888B1 (en) 2011-03-09 2019-05-15 Jitsubo Co., Ltd. Novel cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
MY172862A (en) 2011-03-10 2019-12-13 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivatives
EP2701725A1 (en) 2011-04-29 2014-03-05 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2014520120A (ja) 2011-06-17 2014-08-21 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化した変異型ｍａｍｌペプチドおよびその使用
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
GB201110390D0 (en) 2011-06-20 2011-08-03 Medical Res Council Compounds for use in stabilising p53 mutants
US20120328692A1 (en) 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
AU2012301605A1 (en) 2011-08-31 2014-04-17 New York University Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
SG11201401043SA (en) 2011-09-09 2014-08-28 Agency Science Tech & Res P53 activating peptides
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
WO2013059530A2 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013062923A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CA2761253A1 (en) 2011-12-07 2013-06-07 Vib Vzw Combinations of therapeutic agents for treating melanoma
JP6450191B2 (ja) * 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
US9890429B2 (en) 2012-02-29 2018-02-13 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
WO2013131019A1 (en) 2012-03-02 2013-09-06 Ludwig Institute For Cancer Research Ltd. Iaspp phosphorylation and metastatic potential
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US9371568B2 (en) 2012-07-31 2016-06-21 Novartis Ag Markers associated with human double minute 2 inhibitors
RS61957B1 (sr) 2012-09-26 2021-07-30 Harvard College Uvezani peptidi blokirani prolinom i njihove upotrebe
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
CA2909620A1 (en) 2013-03-13 2014-10-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
JP2016515380A (ja) 2013-03-15 2016-05-30 ライフ テクノロジーズ コーポレーション 肺癌の分類及び実施可能性インデックス
US9198910B2 (en) 2013-04-04 2015-12-01 The Translational Genomics Research Institute Methods for the treatment of cancer
AU2014253932B2 (en) 2013-04-16 2020-04-30 Memorial Sloan-Kettering Cancer Center Companion diagnostic for CDK4 inhibitors
EP3008081B1 (en) 2013-06-14 2017-08-30 President and Fellows of Harvard College Stabilized polypeptide insulin receptor modulators
AU2014286237B2 (en) 2013-07-03 2020-08-20 F. Hoffmann-La Roche Ag mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
US9268662B2 (en) 2013-08-01 2016-02-23 Oracle International Corporation Method and system for a high availability framework
CA2919837A1 (en) 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
CN106103472A (zh) 2013-10-01 2016-11-09 哈佛大学的校长及成员们 稳定化的多肽及其用途
US20160115556A1 (en) 2013-10-19 2016-04-28 Trovagene, Inc. Detecting mutations in disease over time
DK3068393T5 (da) 2013-11-11 2022-08-22 Amgen Inc Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer
ES2785203T3 (es) 2013-12-05 2020-10-06 Hoffmann La Roche Tratamiento de combinación novedoso para leucemia mielógena aguda (LMA)
CN105848682A (zh) 2013-12-23 2016-08-10 诺华股份有限公司 药物组合
EP3094746A1 (en) 2014-01-14 2016-11-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
WO2015157508A1 (en) 2014-04-09 2015-10-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
WO2015179799A1 (en) 2014-05-22 2015-11-26 The General Hospital Corporation DD1alpha RECEPTOR AND USES THEREOF IN IMMUNE DISORDERS
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
KR102570210B1 (ko) 2014-09-24 2023-08-23 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 제제
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
WO2016056673A1 (en) 2014-10-09 2016-04-14 Daiichi Sankyo Company, Limited Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors
US20170227544A1 (en) 2014-10-10 2017-08-10 Hoffmann-La Roche Inc. Methods for personalizing patient cancer therapy with an mdm2 antagonist
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
RU2739942C2 (ru) 2014-12-24 2020-12-30 Дженентек, Инк. Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3317294B1 (en) 2015-07-02 2023-03-15 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
US20170037105A1 (en) 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2996685A1 (en) 2015-09-03 2017-03-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
US20170360881A1 (en) 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2018165575A2 (en) 2017-03-09 2018-09-13 Aileron Therapeutics, Inc. Warhead-containing peptidomimetic macrocycles as modulators of bfl-1

Also Published As

Publication number Publication date
CN112972378A (zh) 2021-06-18
JP2021046436A (ja) 2021-03-25
US20210299211A1 (en) 2021-09-30
US20160101145A1 (en) 2016-04-14
WO2016049355A1 (en) 2016-03-31
EP3197477A1 (en) 2017-08-02
US20230127248A1 (en) 2023-04-27
AU2015320545A1 (en) 2017-04-06
CA2961029A1 (en) 2016-03-31
SG11201702175YA (en) 2017-04-27
AU2015320545C1 (en) 2020-05-14
BR112017005736A2 (pt) 2017-12-12
SG10201902598VA (en) 2019-04-29
JP2022046771A (ja) 2022-03-23
IL251122B (en) 2020-01-30
KR20170063798A (ko) 2017-06-08
KR102570210B1 (ko) 2023-08-23
US10905739B2 (en) 2021-02-02
CN107106642A (zh) 2017-08-29
EP3197477A4 (en) 2018-07-04
JP7219258B2 (ja) 2023-02-07
AU2015320545B2 (en) 2019-11-07
IL251122A0 (en) 2017-04-30
CN107106642B (zh) 2021-02-26
JP2018503595A (ja) 2018-02-08

Similar Documents

Publication Publication Date Title
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
UA122346C2 (uk) ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PH12015502780B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
EA201792591A1 (ru) Фармацевтические препараты
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
EP3590498A4 (en) PREPARATION WITH INCLUDING COMPLEX OF VARENICLINE OR PHARMACEUTICAL SAFE SALT THEREOF FOR ORAL ADMINISTRATION
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
MX2016014699A (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
IL274277A (en) A method for reducing side effects of anti-CD30 drug-antibody couple therapy
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
EP3425388A4 (en) METHOD OF EVALUATING PAIN CAUSED BY ADMINISTRATION OF DRUG SOLUTION, METHOD OF SELECTING DRUG SOLUTION DELIVERY
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
IL273874A (en) A method to reduce the side effects of drug-linked anti-CD30 antibody therapy
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.
PH12016502540A1 (en) Pharmaceutical dosage forms
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.